LONDON--(EON: Enhanced Online News)--Technavio’s latest report on the global hypertrophic cardiomyopathy therapeutics market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
“Genomic medicine is an emerging field in healthcare, which uses gene related information of an individual to help physicians in making better diagnostic and therapeutic decisions. The Human Genome Project has greatly helped in understanding the genetic pathogenesis of a disease and improve the healthcare standards”
The research study by Technavio on the global hypertrophic cardiomyopathy therapeutics market for 2017-2021 provides a detailed industry analysis based on drug-class (calcium channel blockers, beta-adrenergic blockers, antiarrhythmic, and anticoagulants) and geography (the Americas, EMEA, and APAC).
|Hypertrophic cardiomyopathy (HCM) is the enlargement of the heart muscle, which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Technavio analysts forecast the global hypertrophic cardiomyopathy therapeutics market to grow to USD 1,379.69 million by 2021, at a CAGR of close to 2% over the forecast period.|
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three emerging trends driving the global hypertrophic cardiomyopathy therapeutics market according to Technavio healthcare and life sciences research analysts are:
- Increasing availability of genetic tests
- Development of translational bioinformatics (TBI)
- Advent of genomic medicine
Increasing availability of genetic tests
“The increasing availability of genetic tests such as GeneDx, Correlagen, and Transgenomic's FAMILION have greatly helped in determining the pathogenicity in 11 genes causing hypertrophic cardiomyopathy,” says Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorders research.
The HCM individuals are categorized into genotype positive or phenotype negative and phenocopies. The advent of automated DNA sequencing has paved the way for enhanced, reliable, and comprehensive molecular diagnosis of disease. Researchers are putting in continued R&D efforts to come up with even more advanced testing techniques.
Development of translational bioinformatics (TBI)
HCM is a complex genetic disorder, whose diagnosis requires an integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches that allow for the integration and analysis of bioinformatics, biostatics, statistical genetics, and clinical informatics features are termed as TBI. It acts as a data-storage source, which not only performs data integration but also improves data representation using tools such as ontology and controlled vocabulary. The success rate of TBI is increasing patient trust, thereby increasing the adoption of HCM therapeutics.
Advent of genomic medicine
“Genomic medicine is an emerging field in healthcare, which uses gene related information of an individual to help physicians in making better diagnostic and therapeutic decisions. The Human Genome Project has greatly helped in understanding the genetic pathogenesis of a disease and improve the healthcare standards,” says Sapna.
The Human Genome Project paved the way for 'personalized medicine,' which include genomics, epigenomics, and environmental exposure of data related to an individual, which will result in a more precise diagnosis and treatment of a disease. Based on recent discoveries, genomic medicine is expected to fuel the growth of the global HCM therapeutics market.
Browse Related Reports:
- Global Intravenous Iron Drugs Market 2017-2021
- Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021
- Global Dyslipidemia Drugs Market 2017-2021
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, central nervous system, and in-vitro diagnostics. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.
If you are interested in more information, please contact our media team at email@example.com.